Regenecyte is under clinical development by StemCyte and currently in Pre-Registration for Unspecified Hematological Disorders.

Dorocubicel is under clinical development by ExCellThera and currently in Phase II for Blood Cancer. According to GlobalData, Phase II drugs for Blood Cancer have a 34% phase transition success rate ...

Drinking several cups of coffee daily could help reduce cognitive decline in people with atrial fibrillation (AFib), a common ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today ...

The hematology diagnostics market is projected to be valued at USD 780.0 million in 2023 and is rising to USD 2.0 billion by 2033. The market of hematology diagnostics is expected to record a CAGR of ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies ...

The ASH Annual Meeting is recognized as a premier event for hematology research, with more than 5,000 scientific abstracts submitted each year. Accepted abstracts undergo rigorous peer review, with ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases ...

Here's the scoop on the treatment, diagnosis, and definition of the primary brain lymphoma that landed Raphael in the ...

The Government hospitals have issued a statement addressing a video circulating on social media alleging a patient at the ...

The Government hospitals have issued a statement addressing a video circulating on social media alleging a patient at the ...

Kirolos and his family were among dozens who attended the Maimonides Medical Center’s annual holiday party on Dec. 19, where ...